CancerDrs Find care

Thyroid Cancer clinical trials in Ohio

11 actively recruiting thyroid cancer trials at 42 sites across Ohio.

Data from ClinicalTrials.gov · last refreshed

Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Ohio:
  • Local Institution - 2112 — Canton, Ohio
  • Local Institution - 2143 — Cincinnati, Ohio
  • Local Institution - 2109 — Cleveland, Ohio
  • The Ohio State University Wexner Medical Center — Columbus, Ohio
  • Local Institution - 2119 — Toledo, Ohio
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Methimazole in Patients With Progressive Glioblastoma

The purpose of this study is to test the effectiveness, safety, and tolerability of a drug called Methimazole. The investigational drug, Methimazole is not FDA approved for brain tumors, but it is used to treat thyroid illnesses. Different…

Sponsor: Case Comprehensive Cancer Center
NCT ID: NCT05607407
Sites in Ohio:
  • Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center — Cleveland, Ohio
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two par…

Sponsor: Pfizer
NCT ID: NCT05538130
Sites in Ohio:
  • Cleveland Clinic Taussig Cancer Center Investigational Pharmacy — Cleveland, Ohio
  • Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …

Sponsor: Pfizer
NCT ID: NCT05355701
Sites in Ohio:
  • Cleveland Clinic Taussig Cancer Center Investigational Pharmacy — Cleveland, Ohio
  • Cleveland Clinic — Cleveland, Ohio
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cel…

Sponsor: City of Hope Medical Center
NCT ID: NCT03975231
Sites in Ohio:
  • Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Ohio:
  • Summa Health System - Akron Campus — Akron, Ohio
  • Cleveland Clinic Akron General — Akron, Ohio
  • Summa Health System - Barberton Campus — Barberton, Ohio
  • Indu and Raj Soin Medical Center — Beavercreek, Ohio
  • Strecker Cancer Center-Belpre — Belpre, Ohio
View on ClinicalTrials.gov →
NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Ohio:
  • Strecker Cancer Center-Belpre — Belpre, Ohio
  • Adena Regional Medical Center — Chillicothe, Ohio
  • Good Samaritan Hospital - Cincinnati — Cincinnati, Ohio
  • Bethesda North Hospital — Cincinnati, Ohio
  • TriHealth Cancer Institute-Westside — Cincinnati, Ohio
View on ClinicalTrials.gov →
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Ohio:
  • Aultman Alliance Community Hospital — Alliance, Ohio
  • Aultman Hospital — Canton, Ohio
View on ClinicalTrials.gov →
Recruiting Industry

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…

Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Ohio:
  • Research Site — Canton, Ohio
  • Research Site — Maumee, Ohio
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20